Mineralys Therapeutics, Inc. 8-K

What Happened

• Mineralys Therapeutics, Inc. announced on March 12, 2026 (via a press release attached as Exhibit 99.1) its financial results for the quarter and fiscal year ended December 31, 2025 and provided a corporate update. The company filed this announcement on Form 8-K under Item 2.02 (Results of Operations and Financial Condition).
• The Form 8-K notes that the press release is incorporated by reference and includes an Interactive XBRL cover page; it also states that, in accordance with Form 8-K instructions, the information is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Key Details

• Date of filing: March 12, 2026.
• Reporting period: Quarter and fiscal year ended December 31, 2025.
• Disclosure format: Press release attached as Exhibit 99.1 (financial details and corporate update contained in that release).
• Legal note: Information in this Form 8-K (including Exhibit 99.1) is furnished, not "filed," and not subject to Section 18 liability unless expressly incorporated by reference.

Why It Matters

• This 8-K signals that Mineralys has publicly reported its recent earnings and business update; the press release will contain the specific revenue, expense, cash position, and other metrics investors use to evaluate near-term performance.
• Retail investors should read the attached press release (Exhibit 99.1) for the concrete financial figures and management commentary, and watch for any follow-up SEC filings (e.g., 10-K) for audited results and more detailed disclosures.